NCT04796012 2026-04-16
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
Clinical Trials
106 trialsNCT07291076 2026-04-14
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT04802759 2026-04-13
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05286801 2026-04-13
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT06287775 2026-04-13
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT07227597 2026-04-13
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07407933 2026-04-09
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT03533283 2026-04-06
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT05440708 2026-04-06
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Tvardi Therapeutics, Incorporated
Phase 1/2 Recruiting
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT04524871 2026-03-27
MORPHEUS-LIVER
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05142696 2026-03-17
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Novartis
Phase 1/2 Active not recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05468359 2026-03-16
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT02705196 2026-02-24
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
Phase 1/2 Completed
NCT03942328 2026-02-24
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
Phase 1/2 Recruiting
NCT04471727 2026-02-24
MK-6070-001
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2 Active not recruiting
NCT05000294 2026-02-18
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Suspended
NCT03830918 2026-02-12
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT06362252 2026-02-06
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Daiichi Sankyo
Phase 1/2 Recruiting
NCT06939036 2026-02-05
SANTANA-225
Ariceum Therapeutics GmbH
Phase 1/2 Terminated
NCT06771622 2026-02-04
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
Phase 1/2 Active not recruiting
NCT02935361 2026-01-29
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
University of Southern California
Phase 1/2 Active not recruiting
NCT04467723 2026-01-28
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
University of Kansas Medical Center
Phase 1/2 Recruiting
NCT05300282 2026-01-28
FIL_A-BEGEV
Fondazione Italiana Linfomi - ETS
Phase 1/2 Recruiting
NCT03869190 2026-01-22
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Hoffmann-La Roche
Phase 1/2 Completed
NCT05276284 2026-01-14
TEMPLE
Rigshospitalet, Denmark
Phase 1/2 Completed
NCT05450562 2026-01-14
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
Sanofi
Phase 1/2 Terminated
NCT02989584 2026-01-07
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT04691817 2026-01-07
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Abramson Cancer Center at Penn Medicine
Phase 1/2 Recruiting
NCT05039281 2025-12-19
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03281369 2025-12-15
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03337698 2025-12-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Completed
NCT07280377 2025-12-12
GOBLET
Oncolytics Biotech
Phase 1/2 Recruiting
NCT05908786 2025-12-11
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 1/2 Completed
NCT03193190 2025-11-21
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT05434234 2025-11-10
A Study of YL201 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT03901573 2025-10-22
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
NeoImmuneTech
Phase 1/2 Terminated
NCT05703971 2025-10-16
Acclaim-3
Genprex, Inc.
Phase 1/2 Recruiting
NCT05394337 2025-10-09
Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT05052099 2025-09-29
COMBATBIL
University Hospital, Essen
Phase 1/2 Completed
NCT03174197 2025-09-24
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT05652686 2025-09-23
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT05459129 2025-09-15
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT02500407 2025-09-12
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 1/2 Completed
NCT05109442 2025-08-20
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT06294548 2025-08-11
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
University of Alabama at Birmingham
Phase 1/2 Recruiting